Business Wire

TINUBU-SQUARE

10.7.2019 14:02:09 CEST | Business Wire | Press release

Share
Tinubu Square Launches Bonding Insurance Suite

Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, is launching today the Tinubu Bonding Insurance Suite (BIS), which has been developed to serve the surety bonding needs of insurers. The new product is a natural extension of Tinubu Square’s SaaS-based, end-to-end enterprise platform, used widely to help the industry manage and develop its international trade credit insurance, and now its surety bonding activities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005425/en/

The new Tinubu BIS is designed to support surety carriers in their digital transformation journey and to help them to adopt the technologies they need to become more agile and enhance their value proposition to customers.

It draws on Tinubu Square’s long-standing experience delivering solutions that enable insurers to administer the lifecycle of their products from commercial and risk underwriting to claims payment. The same dedication to improving visibility and delivering results has been written into the Bonding Insurance Suite. This will give insurers optimum time to market in what is often a fast moving environment requiring innovative risk distribution strategies. The new solution will allow them to manage an increasing number of bond wordings and signature processes.

Olivier Placca, Tinubu Square Deputy CEO, said: “Tinubu has grown a large and loyal customer base amongst international insurance companies. So, it has become incumbent on us to provide cutting-edge solutions that will support the industry’s business models profitably while helping insurers manage customer-focused strategies. The Bonding Insurance Suite is an extension of our existing, proven software, so it offers opportunities to digitize transactions and take advantage of data assets. It will also ensure that companies are equipped for fluctuating regulations and the particular demands of operating in multiple geographical locations. We have built our considerable knowledge and technical know-how into this new suite and this will be to the advantage of the surety bonding sector during the challenges they face in their digital transformation.”

Key features of the Tinubu Bonding Insurance Suite include:

  • Administration – The capability to manage users, their permissions and authorities within the system. Organisational changes and new staff on-boarding can be easily managed with the profile management tool. Products and their parameters can be created and administered in defined bond categories and associated to bond wordings in the bond library. The suite also includes repository of intermediaries and financial counter-parties to help manage the distribution and production network.
  • Commercial Underwriting – The central repository allows financial statements to be edited or uploaded in Tinubu’s proprietary pivot format and to interface with data providers. Bonding facilities and single bond submissions can be swiftly created, and users will find all the necessary information to manage their customer relationships efficiently.
  • Risk Underwriting – All submission, customer data and diary records are easily accessed, including past assessments and decisions. Thanks to the pdf generator, decision making support material can be created and archived. Dedicated features in the suite allow exposure at the customer level to be aggregated and construction contract execution to be monitored while analysis can be performed across portfolios thanks to Tinubu’s structured data capture of customer, obligee and intermediary information.

User Experience Benefits : Forms and applications can be easily imported into the application and files uploaded in a variety of format using drag and drop. Tinubu has also embedded a diary to centralise documents and archive communications at various levels. Insurers will find that they can give access to their international teams in one single solution available in English, French and Spanish.

About Tinubu Square

Founded in 2000, Tinubu Square is a software vendor, enabler of the Credit Insurance, Surety and Trade Finance digital transformation. Tinubu Square enables organizations across the world to significantly reduce their exposure to risk and their financial, operational and technical costs with best-in-class technology solutions and services. Tinubu Square provides SaaS solutions and services to different businesses including credit insurers, receivables financing organizations and multinational corporations. Tinubu Square has built an ecosystem of customers in over 20 countries worldwide and has a global presence with offices in Paris, London, New York, Montreal and Singapore. For more information: www.tinubu.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye